Nice. So Pulmozyme inadvertently makes Bronchitol more affordable. On a slightly different tack, I always thought that if PXS were prepared to spend the money on a second go with the FDA (which is not a light expense) then they must figure there's a decent return in it from thereon. $4M worldwide is not much at all, so there must be more to this than meets the eye. Otherwise, why would they sink so much into getting FDA approval.
a kicker for bronchitol revenues, page-2
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.002(4.65%) |
Mkt cap ! $56.29M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.5¢ | 4.0¢ | $78.83K | 1.859M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 966640 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 179582 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |